General Updates

28th August, 2026 (1) BSE Limited (2) National Stock Exchange of India Limited Listing Department, Listing Department Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th floor, Dalal Street, Plot no. C/1, G Block, Mumbai 400 001 Bandra Kurla Complex, Bandra (East), Mumbai - 400 051 Scrip Code: 500087 Scrip Code: CIPLA (3) SOCIETE DE LA BOURSE DE LUXEMBOURG Societe Anonyme 35A Boulevard Joseph II, L-1840 Luxembourg Dear Sir/Madam, Sub: Update on USFDA inspection at InvaGen manufacturing facility in Central Islip, Long Island, NY, Dear Sir/Madam, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and further to our intimation dated 18th July, 2026 regarding the United States Food and Drug Administration (USFDA) inspection conducted at the Unit 3 manufacturing facility of InvaGen Pharmaceuticals Inc. (wholly owned subsidiary of the Company) located in Central Islip, Long Island, New York, USA, from 13th July, 2026 to 17th July, 2026 (EDT), we hereby notify that the USFDA vide communication dated 28th August, 2026 has classified the above referred inspection as Voluntary Action Indicated (VAI). Kindly take the above information on record. Yours faithfully, For Cipla Limited Rajendra Chopra Company Secretary Prepared by: Simona Dsouza Cipla Ltd. Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India P +91 22 24826000 W www.cipla.com E-mail contactus@cipla.com Corporate Identity Number L24239MH1935PLC002380